fundamental msb (no chart talk), page-6

I think the answer is the change in strategy, to try to get some therapies to market more quickly.

They haven't abandoned the other therapies, they're just concentrating on going for revenue earlier.

Plus only 3? That's much more than many other stocks have done.

So far no problems with efficacy, look at Sirtex, which has problems and not the same robust platform of technologies to draw on. They are relying on a supplementary use of their technology now.

I'd reread the presos and announcements and give the company a call if you still have concerns. Don't rely on HC for your research.

Take into account that the period of the GFC and post GFC has been difficult for biotechs as funds and stockholders chase yield.

I don't think the SP manipulation is the entire story, but it's a factor IMO.